==== Front Med Mycol Case RepMed Mycol Case RepMedical Mycology Case Reports2211-7539Elsevier S2211-7539(18)30046-010.1016/j.mmcr.2018.04.003Case ReportCandida dubliniensis abscess: A clinical case and a review of the literature Chang Eric Y. eric.young.chang@gmail.coma⁎Fatima Shaheen aBalan Shuba aBhyravabhotla Kshama aErickson Marc aChan Austin abIvonye Chinedu aBradley Cinnamon aa Department of Internal Medicine, Morehouse School of Medicine, 720 Westview Dr. S.W., Atlanta, GA 30310, USAb Division of Infectious Diseases, Department of Internal Medicine, Morehouse School of Medicine, 720 Westview Dr. S.W., Atlanta, GA 30310, USA⁎ Corresponding author. eric.young.chang@gmail.com19 4 2018 9 2018 19 4 2018 21 41 43 25 2 2018 16 3 2018 16 4 2018 © 2018 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.2018This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Candida dubliniensis infections are rare in the absence of prolonged immunocompromised status or intravenous drug abuse. We present a case of a C. dubliniensis soft tissue abscess in a patient with uncontrolled diabetes as his only immunocompromising risk factor, treated with surgical drainage and medical management. Keywords Candida dubliniensisDiabetesFungal soft tissue infection ==== Body 1 Introduction Fungal skin and soft tissue infections are associated with significant morbidity if not identified and treated early. Candida dubliniensis, a lesser known cousin of the infamous Candida albicans, is an opportunistic fungal pathogen most commonly found in the oropharynx of immunocompromised patients or individuals with a pre-existing nidus for infection [1]. However, its presence in patients without these predisposing factors is rare, especially as an isolated abscess. We report a rare case of a C. dubliniensis finger abscess without concomitant fungemia or C. albicans co-infection in a patient with uncontrolled diabetes as his only predisposing risk factor. 2 Case A 56 year-old man with a history of uncontrolled diabetes mellitus type 2 on home insulin presented via emergency medical services after being found down on the street by a bystander. On presentation (Day 0), the patient would open his eyes to voice but was not oriented or able to provide any collateral history. His vital signs were significant for a temperature of 93.2 F, heart rate of 105, and blood pressure of 143/105. Physical exam was limited by the patient's altered mentation and lack of participation but revealed a 2-cm laceration over the dorsum of the right index finger with an associated area of fluctuance that was draining serosanguinous fluid. There were no obvious signs of recent trauma. Labs were significant for a blood glucose of 1600, lactic acid of 6.4, leukocytosis of 17.7, and a significant anion gap metabolic acidosis (44). Urine drug screen, ethanol level, and HIV screening was negative. Urinalysis was significant for 3 + glucose and 1 + ketones. CT head without contrast was negative for any acute intracranial abnormalities. X ray of the right hand was negative for any acute fractures or osseous abnormalities. The patient was immediately transferred to the intensive care unit where he was initiated on early goal directed sepsis protocol and insulin drip for hyperosmolar hyperglycemic syndrome. Blood cultures were obtained and vancomycin and piperacillin-tazobactam were initiated. Orthopedic surgery evaluated the patient and performed a bedside incision and drainage with plans to perform a debridement in the operating room pending medical stability. On day + 2, the patient's mentation remained without improvement. He was taken to the operating room on day + 3 for debridement of the skin and subcutaneous tissue of the right hand abscess due to concerns for systemic infection and to pursue source control and function optimization. Pus and necrotic tissue were evident in the wound with tracking in a dorsal to volar direction through the first and second web spaces. The nonviable tissue was debrided and two sets of tissue were sent for analysis via matrix assisted laser desorption ionization – time of flight mass spectrometry (MALDI-TOF MS), which grew C. dubliniensis susceptible to fluconazole, caspofungin, and voriconazole. However, blood cultures from admission were negative for bacteremia and fungemia. Oral fluconazole (200 mg daily) was initiated but the patient continued to remain lethargic and have persistent purulent drainage from the finger. Repeat debridement was performed in the operating room on day + 10 for further wound assessment and to decrease the risk of secondary infection. Repeat wound cultures were obtained given concerns for possible contamination of the initial cultures but were positive for C. dubliniensis. However, the purulent drainage from the wound ceased. A final debridment and wound closure was performed on day + 15. By this time, the patient was alert, oriented, and back to baseline per his family. The patient was prescribed two additional weeks of fluconazole on discharge with an outpatient appointment for further evaluation to determine if he required additional medication. However, the patient never presented for his follow-up appointment and multiple attempts to contact the patient were unsuccessful. 3 Discussion Candida dubliniensis is a dimorphic yeast that was first isolated in Dublin, Ireland in 1995 by Sullivan et al. who described unusual isolates of oral Candida from HIV/AIDS patient with recurrent oral candida infections [2]. It is very closely related to its more famous cousin, Candida albicans, and shares many phenotypical characteristics including the ability to produce hyphae and chlamydospores [1]. However, C. dubliniensis is rarely found in the oral flora of healthy individuals and is significantly less likely to result in candidemia than C. albicans [3], [4], [5]. Given their similarities, distinguishing between these two closely related species has historically been difficult. However, multiple recent studies and advances in technology have led to increased diagnostic yield [6], [7]. A recent study noted that 128 of 128 C. dubliniensis isolates all produced hyphal fringes after 48–72 h incubation on Pal's agar whereas 124 of 124 C. albicans isolates produced smooth colonies under the same conditions [8]. In addition, species specific polymerase chain reaction (PCR) and MALDI-TOF MS usage has provided more definitive, and rapid, identification methods [3], [9], [10]. These improvements have likely led to an increase in C. dubliniensis recognition and awareness. There have been multiple, invasive C. dubliniensis infections described in the literature, especially in immunocompromised hosts [11], [12] or IV drug abusers [13], [14], [15]. C. dubliniensis fungemia has been noted in allogeneic hematopoietic stem cell transplant patients as well as those who are post cytotoxic chemotherapy [11]. Disseminated C. dubliniensis fungemia with biopsy proven multiorgan involvement in an HIV patient has been described [16]. Other reported cases include C. dubliniensis spondylodiscitis in both HIV-1 patients [12] and intravenous (IV) drug abusers [15], spinal abscess in an IV drug user [12], and healthcare-associated catheter-related blood stream infections [17]. In addition, other complications include endocarditis in IV drug abusers [12] and endophthalmitis in both intravenous drug users and patients with no such history [18], [19]. In general, fungal soft tissue infections are uncommon [20]. If present, C. albicans is the most common organism but polymicrobial infections are often seen, with staphylococcus and streptococcus the most frequently isolated pathogens [20]. However, per literature review, there has been an increase in reported C. dubliniensis infections, especially in immunocompromised individuals, most likely due to an improvement in identification methods via PCR and MALDI-TOF MS [3], [9], [10]. In the absence of an immunocompromised state, other reported risk factors include a history of surgery, the presence of indwelling catheters [16], [17], or even frenulum piercings [11]. Given that necrotizing soft tissue infections have the potential to be fatal, high index of clinical suspicion and timely intervention is critical. The use of MALDI-TOF MS for fungal pathogen identification has been gaining increasing awareness due to its ability to rapidly distinguish between closely related species such as C. dubliniensis and C. albicans [10]. Conventional methods (CI) for identification include analysis of phenotypic properties such as morphological and biochemical properties related to assimilation and fermentation of substrates, and may take up to five days for identification [10]. Given that these methods are based off of phenotypic characteristics, the results may be vague, leading to subsequent time-consuming gene analysis for confirmation. In contrast, identification through MALDI-TOF MS can be performed within 2 h from a pure culture [10]. More importantly, a recent analysis of MALDI-TOF MS vs CI revealed that when a discordance of C. dubliniensis identification was revealed between these two methods, confirmatory studies with PCR and gene sequencing showed that MALDI-TOF MS was able to correctly identify C. dubliniensis in all samples (11/11) while CI was not able to identify any (0/11), highlighting the powerful potential of MALDI-TOF MS to rapidly distinguish between these two closely related species [10]. Management of patients suspected to have C. dubliniensis soft tissue or skin infection begins with timely clinical judgment in addition to obtaining multiple blood cultures and initiating broad spectrum antibiotics, antifungals, and supportive management to control fungal infection spread while preventing secondary bacterial infection. Once the patient is hemodynamically stabilized, source control should be prioritized with surgical involvement for debridement as appropriate. In our patient's case, multiple debridement sessions were required for proper source control and he was treated with fluconazole per Infectious Disease Society of America (IDSA) treatment guidelines for Candida skin and soft tissue abscess treatment. A lack of improvement may signal fluconazole resistance [18], which has been reported in the literature. Other treatment options include intravenous caspofungin, anidulafungin, and other azoles. 4 Conclusion This patient is the first reported case, to our knowledge, of an isolated C. dubliniensis abscess without fungemia in a patient with uncontrolled diabetes mellitus as his only immunocompromising factor, who was treated effectively with surgical debridement and fluconazole. C. dubliniensis should be considered an emerging threat, rather than being dismissed as a colonizer or contaminant. Proper management of patients suspected of fungal infections requires both medical and surgical management to optimize source control and prevent secondary infections. Acknowledgements The authors do not have any other individuals to acknowledge. Conflict of interest The authors have no conflicts of interest to declare. ==== Refs References 1 Ventolini G. Tsai P. Moore L.D. C. Dubliniensis in an immunocompetent patient with metal lingual frenulum piercing Med. Mycol. Case Rep. 14 2016 27 29 28018842 2 Sullivan D.J. Westerneng T.J. Haynes K.A. Bennett D.E. Coleman D.C. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals Microbiology 141 Pt7 1995 1507 1521 7551019 3 Jabra-Rizk M.A. Johnson J.K. Forrest G. Mankes K. Meiller T.F. Venezia R.A. Prevalence of Candida dubliniensis fungemia at a large teaching hospital Clin. Infect. Dis. 41 7 2005 1064 1067 16142677 4 Sullivan D.J. Moran G.P. Pinjon E. Al-Mosaid A. Stokes C. Vaughan C. Comparison of the epidemiology, drug resistance, mechanisms, and virulence of Candida dubliniensis and Candida albicans FEMS Yeast Res. 4 4–5 2004 369 376 14734017 5 Brandt M.E. Harrison L.H. Pass M. Sofair A.N. Huie S. Li R.K. Candida dubliniensis fungemia: the first four cases in North America Emerg. Infect. Dis. 6 1 2000 46 49 10653569 6 Muthig M. Hebestreit A. Ziegler U. Seidler M. Muller F.M. Persistence of Candida species in the respiratory tract of cystic fibrosis patients Med. Mycol. 48 1 2010 56 63 19184771 7 Chotirmall S.H. O’Donoghue E. Bennett K. Gunaratnam C. O’Neill S.J. Mc Elvaney N.G. Sputum Candida albicans presages FEV1 decline and hospitalized treated exacerbations in cystic fibrosis Chest 138(5) 138 2010 1185 1195 8 Al-Mosaid A. Sullivan D.J. Coleman D.C. Differentiation of Candida dubliniensis from Candida albicans on Pal's Agar J. Clin. Microbiol. 41 10 2003 4787 4789 14532221 9 Sebti A. Kiehn T.E. Perlin D. Chaturvedi V. Wong M. Doney A. Candida dubliniensis at a cancer center Clin. Infect. Dis. 32 7 2001 1034 1038 11264031 10 Sendid B. Ducoroy P. Francois N. Lucchi G. Spinali S. Vagner O. Evaluation of MALDI-TOF mass spectrometry for the identification of medically-important yeasts in the clinical laboratories of Dijon and Lille hospitals Med. Mycol. 51 1 2013 25 32 22703164 11 Meis J.F. Ruhnke M. De Pauw B.E. Odds F.C. Siegert W. Verweij P.E. Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation Emerg. Infect. Dis. 5 1 1999&;; 150 153 10081684 12 Salzer H.J. Rolling T. Klupp E.M. Schmiedel S. Hematogenous dissemination of Candida dubliniensis causing spondylodiscitis and spinal abscess in a HIV-1 and HCV-coinfected patient Med. Mycol. Case Rep. 8 2015 17 20 25750857 13 Sullivan D. Coleman D. Candida dubliniensis: characteristics and Identification J. Clin. Microbiol 36 2 1998 329 334 9466736 14 Carr M.J. Clarke S. O’Connell F. Sullivan D.J. Coleman D.C. OConnell B. First reported case of endocarditis caused by candida dubliniensis J. Clin. Microbiol. 43 6 2005 3023 3026 15956451 15 Oksi J. Finnila T. Hohenthal U. Rantakokko-Jalava K. Candida dubliniensis spondylodiscitis in an immunocompetent patient Case Report. Rev. Lit. Med. Mycol. Case Rep. 3 2013 4 7 16 Chan-Tack K.M. Fatal Candida dubliniensis Septicemia in a Patient with AIDS Clin. Infect. Dis. 40 8 2005 1209 1210 15791525 17 Lai C.C. Tsai H.Y. Chang T.C. Hsueh P.R. Catheter-related fungemia caused by Candida dubliniensis J. Microbiol. Immunol. Infect. 46 4 2013 306 308 23246304 18 Moran G.P. Sullivan D.J. Henman M.C. McCreary C.E. Harrington B.J. Shanley D.B. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro Antimicrob. Agents Chemother. 41 3 1997 617 623 9056003 19 Espinosa-Heidmann D.G. McMillan B.D. Lasala P.R. Stanley J. Larzo C.R. Candida dubliniensis endophthalmitis: first case in North America Int. Ophthalmol. 32 1 2012 41 45 22222717 20 Buchanan P.J. Mast B.A. Lottenberg L. Kim T. Efron P.A. Ang D.N. Candida albicans necrotizing soft tissue infection: a case report and literature review of fungal necrotizing soft tissue infections Ann. Plast. Surg. 70 6 2013 739 741 23123606